850 JAK-STAT platform for immune-related drug discovery

<h3>Background</h3> The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways are evolutionarily conserved transmembrane signaling mechanisms that ensure the ability of normal cellular communication with the external environment. Various cytokines, interferons, growth factors, and other specific molecules can activate JAK-STAT signaling to drive a range of physiological and pathological processes, including proliferation, metabolism, immune response, inflammation, and malignancy. However, the JAK-STAT signaling pathway and related gene mutations are closely associated with aberrant immune activation and cancer progression. Through extensive research into the structure and function of the JAK-STAT pathway, a variety of clinical drugs have emerged and been approved for the treatment of disease, primarily targeting cytokines and their receptors, JAK inhibitors and STAT inhibitors. <h3>Methods</h3> Both JAK and STAT, once activated, cause STAT phosphorylation and the amount of downstream cytokines secreted. Therefore by using different cytokines such as IL-6, IL-23, IFNα, TPO or GM-CSF, etc., stimulating PBMC, T cells or whole blood, and detecting STAT phosphorylation as well as secreted cytokines, the activity of various drugs on the JAK-STAT pathway can be assessed. <h3>Results</h3> Whether it is THP-1 cells, PBMC or monocyte-induced macrophages, once NLRP3 is inhibited after LPS stimulation, it can effectively inhibit the secretion of IL-1β or IL-18, as well as caspase-1 activity, and by analyzing the amount of cytokine secretion or caspase1 activity, we can assess the inhibitory activity of different types of compounds on NLRP3. <h3>Conclusions</h3> Both in PBMC and in sorted T cells as well as whole blood, various JAK-STAT-related inhibitors can be validated for their activity by assaying STAT phosphorylation as well as cytokines. Currently, ICE has established various in vitro assays for the JAK-STAT signaling pathway to facilitate drug discovery.

Authors

Institutions

Publication Details

Journal
Regular and Young Investigator Award Abstracts
Published
2024-11-01
DOI
https://doi.org/10.1136/jitc-2024-sitc2024.0850
Primary Topic
Cytokine Signaling Pathways and Interactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

850 JAK-STAT platform for immune-related drug discovery

Tao Bing, Louis Yi Ann Chai, Peng Liu
Regular and Young Investigator Award Abstracts
Cytokine Signaling Pathways and Interactions
article

850 JAK-STAT platform for immune-related drug discovery

Tao Bing, Louis Yi Ann Chai, Peng Liu
article en

Abstract

<h3>Background</h3> The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways are evolutionarily conserved transmembrane signaling mechanisms that ensure the ability of normal cellular communication with the external environment. Various cytokines, interferons, growth factors, and other specific molecules can activate JAK-STAT signaling to drive a range of physiological and pathological processes, including proliferation, metabolism, immune response, inflammation, and malignancy. However, the JAK-STAT signaling pathway and related gene mutations are closely associated with aberrant immune activation and cancer progression. Through extensive research into the structure and function of the JAK-STAT pathway, a variety of clinical drugs have emerged and been approved for the treatment of disease, primarily targeting cytokines and their receptors, JAK inhibitors and STAT inhibitors. <h3>Methods</h3> Both JAK and STAT, once activated, cause STAT phosphorylation and the amount of downstream cytokines secreted. Therefore by using different cytokines such as IL-6, IL-23, IFNα, TPO or GM-CSF, etc., stimulating PBMC, T cells or whole blood, and detecting STAT phosphorylation as well as secreted cytokines, the activity of various drugs on the JAK-STAT pathway can be assessed. <h3>Results</h3> Whether it is THP-1 cells, PBMC or monocyte-induced macrophages, once NLRP3 is inhibited after LPS stimulation, it can effectively inhibit the secretion of IL-1β or IL-18, as well as caspase-1 activity, and by analyzing the amount of cytokine secretion or caspase1 activity, we can assess the inhibitory activity of different types of compounds on NLRP3. <h3>Conclusions</h3> Both in PBMC and in sorted T cells as well as whole blood, various JAK-STAT-related inhibitors can be validated for their activity by assaying STAT phosphorylation as well as cytokines. Currently, ICE has established various in vitro assays for the JAK-STAT signaling pathway to facilitate drug discovery.

Regular and Young Investigator Award Abstracts
Bioscience (China) (CN)
Openalex Percentile: Top 65%
Cytokine Signaling Pathways and Interactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.